in a study of 41 patients with relapsed and refractory CLL having received anti-CD19-CART retrospectively associated complete remissions following CART therapy with an increased frequency of a class of memory-like CD8+CD27+CD45RO- T-cells in the leukapheresis sample prior to CART manufacture based on cluster analysis (68). This evidence concerns the gene CD27 and B-cell chronic lymphocytic leukemia.